Swiss pharmaceutical giant Novartis AG (NYSE: NVS ) is reportedly contemplating selling sections of radiopharmaceuticals company Advanced Accelerator Applications to align with the company''s strategy and the broader industry trend to shed low-growth segments. Novartis is currently in the initial phase of assessing a potential sale. Although discussions are underway, there remains uncertainty surrounding the outcome, emphasizing that a deal is not guaranteed, Bloomberg reports. Advanced Accelerator Applications produces radioactive medicines treating ailments like cancer and is a pioneer in molecular imaging, aiding in the … Full story available on Benzinga.com

Novartis CEO Vas Narasimhan joins ''Squawk on the Street'' to discuss the company''s new spin-off Sandoz, what a pure-play core pharmaceutical company means, and the idea of M&A to boost the company''s growth prospects.

Novartis CEO Vas Narasimhan joins ''Squawk on the Street'' to discuss the company''s new spin-off Sandoz, what a pure-play core pharmaceutical company means, and the idea of M&A to boost the company''s growth prospects.

Novartis AG is considering selling part of radiopharmaceuticals company Advanced Accelerator Applications, people with knowledge of the matter said, as it joins an industry-wide push to cast off low-growth business lines.

Vas Narasimhan, CEO at Novartis, discusses the company''s 100% spin off of Sandoz, its generic and biosimilar medicines business, and what the deal means for shareholders.

… health program, including Amgen and Novartis , said they signed on to … (FDA) has declined to approve Eli Lilly ''s drug to treat … its weight-loss and diabetes drugs Wegovy and Ozempic brought … denied the requests by Mylan Pharmaceuticals , which is owned by …

(CTN News) – A new drug being studied to treat a rare kidney disease received positive interim results from Novartis on Monday. According to Novartis, the treatment, Iptacopan, has achieved significant clinical results over a nine-month period in a study, called APPLAUSE-IgAN, for patients with immunoglobulin A (IgA) nephropathy, or IgAN. There is a rare […]

Novartis has announced positive interim results for iptacopan from the Phase III Applause-IgAN study showing significant proteinuria reduction in patients with IgA nephropathy (IgAN). IgAN is a complement-mediated chronic kidney disease where the …

Swiss pharmaceutical giant Novartis on Monday reported positive interim Phase III results for a new drug being studied to treat a rare kidney disease.

BASEL (dpa-AFX) - Novartis (NVS) said that an investigational phase III study of iptacopan demonstrated clinically meaningful and highly statistically significant proteinuria reduction in patients…